ProCE Banner Activity

Phase II INSIGHT 2: Primary Analysis of Tepotinib + Osimertinib for Advanced EGFR-Mutated NSCLC With MET Amplification Following First-line Osimertinib

Conference Coverage

Combination therapy with the MET TKI tepotinib plus osimertinib demonstrated an ORR of 50% and median duration of response of 8.5 months with a manageable safety profile in patients with MET-amplified, EGFR-mutated advanced NSCLC after disease progression on first-line osimertinib.

Released: September 20, 2023


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc, Gilead Sciences Inc., and Regeneron Pharmaceuticals, Inc.


Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

Regeneron Pharmaceuticals, Inc